Prehospital continuous positive airway pressure for acute respiratory failure: the ACUTE feasibility RCT

Gordon W Fuller,1* Samuel Keating,2 Steve Goodacre,1 Esther Herbert,2 Gavin D Perkins,3 Andy Rosser,4 Imogen Gunson,4 Joshua Miller,4 Matthew Ward,4 Mike Bradburn,2 Praveen Thokala,5 Tim Harris,6 Margaret M Marsh,7 Alexander J Scott2 and Cindy Cooper2

1Centre for Urgent and Emergency Care Research, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2Clinical Trials Research Unit, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
3Warwick Clinical Trials Unit, University of Warwick, Coventry, UK
4West Midlands Ambulance Service, Brierley Hill, UK
5Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
6Centre for Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, London, UK
7Sheffield Emergency Care Forum, Royal Hallamshire Hospital, Sheffield, UK

*Corresponding author g.fuller@sheffield.ac.uk

Declared competing interests of authors: Steve Goodacre is Deputy Director of the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (2016–present), chairperson of the NIHR HTA Commissioning Board (2016–present) and a member of the NIHR HTA Funding Strategy Group (2016–present). Esther Herbert reports grants from NIHR during the conduct of the study, outside the submitted work. Gavin Perkins is a NIHR Senior Investigator and a member of the Programme Grants for Applied Research board (2016–present). Cindy Cooper is a member of the NIHR Clinical Trials Unit Standing Advisory Committee (2016–present) and of the UK Clinical Research Collaboration Registered Clinical Trials Unit Network Executive Group (2016–present).

Disclaimer: This report contains transcripts of interviews conducted in the course of the research and contains language that may offend some readers.

Published February 2021
DOI: 10.3310/hta25070
Scientific summary

The ACUTE feasibility RCT
Health Technology Assessment 2021; Vol. 25: No. 7
DOI: 10.3310/hta25070

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Acute respiratory failure is a serious acute illness that occurs when diseases of the heart or lungs lead to failure of the respiratory system, over minutes or hours, in one or both of its gas exchange functions (oxygenation and carbon dioxide elimination). Common causes of acute respiratory failure include heart failure, pneumonia, chronic obstructive pulmonary disease, pulmonary embolism and asthma. The incidence of acute respiratory failure has been estimated at 80 cases per 100,000 per year. The overall risk of death is high, with estimates of 30-day mortality ranging between 14% and 20%. Acute respiratory failure has substantial health services costs, with patients often requiring prolonged hospital stays, ventilatory support and critical care admissions. Acute respiratory failure accounts for over 3 million NHS bed-days and hospital costs of £9.6M per year in England.

Current prehospital management of acute respiratory failure in the NHS uses a standard management approach of controlled oxygen therapy, supplemented by specific ancillary treatments directed at the underlying disease. Continuous positive airway pressure involves delivering oxygen-enriched air to the lungs at increased pressure through a tight-fitting face mask. Continuous positive airway pressure is widely used in hospitals to treat acute respiratory failure from a number of causes, and it has been suggested that it may be more effective if delivered earlier (i.e. en route to hospital). The difficulties of prehospital diagnosis mean that prehospital continuous positive airway pressure is likely to be applied generally to all cases of acute respiratory failure, rather than directed towards certain patients owing to a specific cause.

Existing research investigating prehospital continuous positive airway pressure is inconclusive. A previous Health Technology Assessment programme evidence synthesis [Pandor A, Thokala P, Goodacre S, Poku E, Stevens JW, Ren S, et al. Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. *Health Technol Assess* 2015;19(42)] suggested that prehospital continuous positive airway pressure could be effective in reducing mortality and intubation rates. However, included studies were deemed to be at a high risk of bias and the findings were not generalisable to the NHS. None of the included studies was undertaken in the UK and the methods used to deliver prehospital continuous positive airway pressure (physician or paramedics with online physician support) would not reflect normal NHS practice. An economic model developed for the same project suggested that prehospital continuous positive airway pressure was more effective than standard care, but was also more expensive, with an incremental cost-effectiveness ratio of £20,514 per quality-adjusted life-year. The model also indicated that further research costing up to £22.5M could represent value for money.

Although prehospital continuous positive airway pressure is a promising therapy, further research is needed to examine whether or not the reported clinical effectiveness and cost-effectiveness are confirmed in the UK setting, with unsupported paramedic delivery and limited additional training. Prior to a large pragmatic trial and economic evaluation, it is first necessary to estimate the incidence of eligible patients to determine whether or not a trial would be feasible and cost-effective. It is also important to determine whether or not prehospital continuous positive airway pressure can be delivered successfully in the context of the NHS ambulance services. For these reasons, a stand-alone feasibility study is necessary to estimate the incidence of eligible patients, to test the feasibility and acceptability of potential definitive trial methods, and to address important uncertainties, such as patient selection, delivery of the intervention and event rates.
Objectives

Primary objectives were to estimate the following feasibility outcomes:

- The rate of eligible patients per 100,000 persons per year.
- The proportion of participants recruited and allocated to treatment appropriately.
- Adherence to allocated treatment.
- Retention and data completeness up to 30 days.

Secondary objectives were to estimate the following summary clinical outcome measures:

- The proportion of participants surviving to 30 days.
- The proportion of participants undergoing endotracheal intubation by 30 days.
- The proportion of participants admitted to critical care at any point up to 30 days.
- The mean and median lengths of hospital stay.
- Change in visual analogue scale dyspnoea score from presentation to immediately before emergency department arrival.
- The mean EuroQol-5 Dimensions, five-level version, score at 30 days.
- Key elements of health-care resource use up to 30 days.

Methods

Pilot trial
An open-label, individual patient randomised, parallel-arm, controlled, external pilot trial was conducted to determine the feasibility of a definitive trial evaluating the clinical effectiveness and cost-effectiveness of prehospital continuous positive airway pressure compared with standard oxygen therapy in acute respiratory failure. A sample size of 120 participants was planned, allowing mortality to be estimated with a standard error of 2.7% for use in the sample size calculation of an eventual large-scale trial and estimation of feasibility outcomes with a precision of < 5%.

Recruitment took place across four West Midlands Ambulance Service hubs between August 2017 and July 2018. Adults with respiratory distress and peripheral oxygen saturation below the British Thoracic Society’s target levels, despite supplemental oxygen, were eligible. Patients with pre-existing lack of capacity, or with limited potential to benefit from, or contraindications to, continuous positive airway pressure were excluded.

Participants in the intervention arm were treated with prehospital continuous positive airway pressure (O-Two unit, O-Two Medical Technologies Inc., Brampton, ON, Canada). Participants in the control arm received standard oxygen therapy. Ancillary condition-specific treatments were administered in both arms according to standard practice guidelines. Interventions were provided in identical sealed boxes to ensure allocation concealment. Participants were individually randomised in a 1 : 1 ratio using simple randomisation, constrained by the maximum number of boxes supplied for trial use (n = 160).

Feasibility outcomes comprised incidence of eligible patients (target 120); the proportion recruited and allocated to treatment appropriately (target ≥ 90); adherence to allocated treatment (target ≥ 75%); and retention and data completeness (target ≥ 90%). Effectiveness outcomes were survival at 30 days (definitive trial primary end point); endotracheal intubation; admission to critical care; length of hospital stay; EuroQol-5 Dimensions, five-level version, score; and health-care resource use at 30 days.

Economic evaluation
Cost-effectiveness and value-of-information analyses were also performed, updating the previously described economic model and evidence synthesis with data from the Ambulance continuous positive airway pressure trial.
airway pressure (CPAP): Use, Treatment Effect and economics (ACUTE) pilot trial. Prehospital continuous positive airway pressure and standard care were compared in a probabilistic sensitivity analysis following the National Institute for Health and Care Excellence base-case recommendations. The cost-effectiveness of the different interventions was estimated using the incremental cost-effectiveness ratio approach. The population expected value of perfect information and expected value of partial perfect information were calculated to indicate the cost-effectiveness of further research.

Ancillary substudies
West Midlands Ambulance Service patient records between 1 August 2017 and 31 July 2018 were electronically screened and examined by research paramedics to identify patients presenting with acute respiratory failure who were potentially eligible for the ACUTE trial. The incidence rate was then calculated using a population denominator determined from Office for National Statistics data. Agreement between the prehospital clinical impression and final hospital diagnosis was compared for patients enrolled in the pilot trial. The experiences of ambulance service clinicians participating in the ACUTE trial were examined in a mixed-methods study consisting of a survey and focus groups. The robustness of allocation concealment was investigated in a convenience sample of no-trial ambulance service clinicians from Yorkshire Ambulance Service and West Midlands Ambulance Service. Clinician participants were asked to indicate whether or not they could differentiate between a randomly selected pair of control and intervention arm boxes.

Results

Pilot trial
Over 12 months, 77 participants were enrolled (continuous positive airway pressure arm, n = 42; standard oxygen control arm, n = 35; target, n = 120). Continuous positive airway pressure was fully delivered as planned in 74% of intervention arm participants (target 75%). There were no major protocol violations or non-compliances (target 0%). Full data were available for key outcomes, including all feasibility end points and vital status at 30 days (targets of ≥ 90%). There was missing information on other clinical outcomes, with data completeness ranging from 79% to 100%.

Mortality was higher than expected [overall 27.3%: continuous positive airway pressure arm, n/N = 12/42 (28.6%); standard care arm, n/N = 9/35 (25.7%)]. Of the 21 deceased participants, 14 (68%) either did not have a respiratory condition or had explicit or implicit ceiling-of-treatment decisions, which excluded hospital non-invasive ventilation or critical care. The risk of intubation was low (overall 4.8%: continuous positive airway pressure arm, 6.1%; standard care arm, 3.4%) and only a small proportion of participants were admitted to critical care (overall 9.2%: continuous positive airway pressure arm, 11.4%; standard care arm, 6.7%).

Hospital length of stay was similar for both trial arms (continuous positive airway pressure arm, median 10 days; standard oxygen therapy arm, median 7 days). Breathlessness was similar across trial arms and improved over the prehospital interval from an initial clinician-assessed visual analogue scale median score of 9 out of 10 (n = 76, interquartile range 8–10) to 6 out of 10 (n = 76, interquartile range 5–8) on arrival at hospital. The median follow-up EuroQol-5 Dimensions, five-level version, score at 30 days was 0.82 (n = 22, interquartile range 0.58–0.95) in the continuous positive airway pressure arm and 0.73 (n = 18, interquartile range 0.43–0.89) in the standard care arm.

Adverse events related to continuous positive airway pressure comprised mild claustrophobia or distress associated with continuous positive airway pressure mask use. Two participants were diagnosed with a pneumothorax in the emergency department (expected related serious adverse events, neither receiving continuous positive airway pressure). There were no other expected or unexpected related serious adverse events.
Economic evaluation
The base-case analysis, using continuous positive airway pressure effectiveness estimates from the ACUTE pilot trial, indicated that a standard oxygen therapy strategy was likely to be cost-effective at a threshold of £20,000 per quality-adjusted life-year (mean incremental cost-effectiveness ratio £5685/quality-adjusted life-year, 67% probability). Values-of-information analyses demonstrated that there was considerable uncertainty about whether or not to adopt prehospital continuous positive airway pressure. Base-case population expected value of perfect information suggested that it would be worth spending up to £16.5M on further research. Expected value of partial perfect information analysis indicated that the effectiveness of prehospital continuous positive airway pressure on mortality was the only important variable for future investigation (expected value of partial perfect information was £16.5M, expected value of partial perfect information was zero for all other model parameters).

Ancillary substudies
Between 1 August 2017 and 31 July 2018, a total of 1017 patients were identified from the West Midlands Ambulance Service with acute respiratory failure and eligibility for the ACUTE pilot trial, giving an overall incidence rate of 17.4 per 100,000 persons per year (95% confidence interval 16.3 to 18.5 per 100,000 persons per year).

The most common final hospital diagnoses for acute respiratory failure were chronic obstructive pulmonary disease (21/65, 32.3%) and lower respiratory tract infection (28/65, 43.1%). In seven cases (10.8%), a final diagnosis was present in which continuous positive airway pressure would not be expected to be effective, or could be harmful; these included myocardial infarction, ruptured abdominal aortic aneurysm, liver failure, sepsis and pneumothorax. There was moderate agreement between the primary prehospital and hospital diagnoses (raw agreement 58.5%, Gwet’s AC1 coefficient 0.56, 95% confidence interval 0.43 to 0.69).

Ambulance service clinicians felt confident in the diagnosis of acute respiratory failure, determining trial eligibility and delivering continuous positive airway pressure. Important factors identified as facilitators of participation in the pilot trial were ease of use of trial boxes and trial documentation, and simplicity of consent processes. Conversely, lack of awareness of the ACUTE trial in receiving hospitals, limited time to complete web-based trial training and a desire to provide continuous positive airway pressure treatment were highlighted as important challenges.

During week 10 of recruitment, some intervention arm equipment boxes began to ‘rattle’. After repackaging and redistribution, no further concerns were noted during weekly randomisation schedule audits. Of the 278 ambulance service clinicians participating in the allocation concealment substudy, 58.6% were unable to distinguish a difference between control and intervention arm boxes. Of the participants indicating a difference, 70.4% (95% confidence interval 61.1% to 78.4%) correctly chose continuous positive airway pressure.

Conclusions
The pilot trial recruitment rate was below the target rate and feasibility was not demonstrated. The economic evaluation results suggested that a large definitive trial could represent value for money. However, the limited compliance with continuous positive airway pressure and the trial population, including patients who could not benefit from continuous positive airway pressure, indicate that a clinically significant effect size is not plausible. A definitive clinical effectiveness trial of continuous positive airway pressure in the NHS is therefore not recommended. These findings also argue against routine implementation of continuous positive airway pressure in NHS ambulance services, but would not preclude a continuous positive airway pressure service provided by clinicians, with extended training (e.g. prehospital physicians), which might allow selective targeting of treatment to an appropriate subgroup of patients.
Trial registration

This trial is registered as ISRCTN12048261.

Funding

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 25, No. 7. See the NIHR Journals Library website for further project information.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 15/08/40. The contractual start date was in July 2016. The draft report began editorial review in April 2019 and was accepted for publication in October 2019. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2021. This work was produced by Fuller et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont  Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk